Variation at the NFATC2 locus increases the risk of thiazolidinedione- induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study

Diabetes Care

Volumn 33, Issue 10, 2010, Pages 2250-2253

  Bailey, Swneke D ^a   Xie, Changchun ^b,c   Do, Ron ^a   Montpetit, Alexandre ^a   Diaz, Rafael ^d   Mohan, Viswanathan ^e   Keavney, Bernard ^f   Yusuf, Salim ^b,c   Gerstein, Hertzel C ^b,c   Engert, James C ^a   Anand, Sonia ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Estudios Cardiologicos Latino America   (Argentina)

^e MADRAS DIABETES RESEARCH FOUNDATION   (India)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC2; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; ETHNIC GROUP; EUROPE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AND CENTRAL AMERICA; STROKE; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; EDEMA; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; NFATC TRANSCRIPTION FACTORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RAMIPRIL; THIAZOLIDINEDIONES;

EID: 79951685120     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-0452     Document Type: Article

References (15)

1. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350 (Pubitemid 32378388)
2. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118
3. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-1611
4. Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007;76:279-289 (Pubitemid 46400130)
5. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-1136 (Pubitemid 47464583)
6. Cho S, Atwood JE. Peripheral edema. Am J Med 2002;113:580-586 (Pubitemid 35379914)
7. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105
8. Ruaño G, Bernene J, Windemuth A, Bower B, Wencker D, Seip RL, Kocherla M, Holford TR, Petit WA, Hanks S. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clin Chim Acta 2009;400:48-55
9. Geese WJ, Achanzar W, Rubin C, Hariharan N, Cheng P, Tomlinson L, Ordway N, Dracopoli NC, Delmonte T, Hui L, Krishnan B, Cosma G, Ranade K. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists. Pharmacogenet Genomics 2008;18:903-910
10. Hansen L, Ekstrøm CT, Tabanera Y, Palacios R, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist- induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006;91:3446-3450 (Pubitemid 44402117)
11. Spraggs C, McCarthy A, McCarthy L, Hong G, Hughes A, Lin X, Sathe G, Smart D, Traini C, Van Horn S, Warren L, Mosteller M. Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar. Pharmacogenet Genomics 2007;17:1065-1076 (Pubitemid 351339491)
12. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell 2002;109(Suppl.):S67-S79 (Pubitemid 34457853)
13. Bao Y, Li R, Jiang J, Cai B, Gao J, Le K, Zhang F, Chen S, Liu P. Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway. Mol Cell Biochem 2008;317:189-196
14. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin- dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-228 (Pubitemid 28180855)
15. Bourajjaj M, Armand AS, da Costa Martins PA, Weijts B, van der Nagel R, Heeneman S, Wehrens XH, De Windt LJ. NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. J Biol Chem 2008;283:22295-22303